Genmab reported 1.18B in Operating Expenses for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Agios Pharmaceuticals AGIO:US $ 89.22M 2M
Alexion Pharmaceuticals ALXN:US $ 1000.3M 30.6M
Amarin AMRN:US 145.72M 2.21M
Amgen AMGN:US $ 5.7B 1.93B
AstraZeneca AZN:LN 7.09B 1.67B
Bayer BAYN:GR 13.14B 3.89B
Biomarin Pharmaceutical BMRN:US $ 490.02M 29.08M
Bluebird Bio BLUE:US $ 248.31M 4.31M
Exelixis EXEL:US $ 262.17M 12.67M
Fresenius Medical Care FME:GR 3.9B 160M
Galapagos GLPG:NA 199.82M 24.86M
Genmab GEN:DC 1.18B 136M
GlaxoSmithKline GSK:LN 6.42B 692M
GN Store Nord GN:DC 3.19B 204M
H. Lundbeck A/S LUN:DC 3.36B 27M
Hikma Pharmaceutical HIK:LN 873M 27M
Immunogen IMGN:US $ 44.32M 305K
Insmed INSM:US $ 151.62M 27.57M
Lonza Group LONN:SW 2.22B 1.07B
Merck MRK:GR 3.82B 233M
Novartis NOVN:VX 9.82B 464M
Regeneron Pharmaceuticals REGN:US $ 1791.3M 375.3M
Seattle Genetics SGEN:US $ 478.08M 23.68M
William Demant Holding WDH:DC 7.37B 399M